<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104118">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01806961</url>
  </required_header>
  <id_info>
    <org_study_id>SP848-AKEx-1209</org_study_id>
    <nct_id>NCT01806961</nct_id>
  </id_info>
  <brief_title>Observational Trial Assessing Long-term Local Tolerability and Efficacy of Resiquimod Gel in Patients Treated for Actinic Keratosis.</brief_title>
  <official_title>Observational (Non-interventional), Follow-up Trial Assessing Long-term Local Tolerability and Efficacy (Recurrence Rate) of Resiquimod Gel in Patients Treated for Actinic Keratosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spirig Pharma Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spirig Pharma Ltd.</source>
  <oversight_info>
    <authority>Switzerland: Ethikkommission</authority>
    <authority>Switzerland: Swissmedic</authority>
    <authority>Germany: Ethics Commission</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine the recurrence rate of actinic keratosis (AK) lesions in patients with complete
      clinical clearance at the end of the previous trial SP848-AK-1101 at 6 and 12 months of
      follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Determine the recurrence rate of AK-lesions</measure>
    <time_frame>at 6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with persistent complete clearance at 6 and 12 months follow-up. Recurrence rate is to be determined at the same treatment area where the investigational medicinal products were administered in the previous trial.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of new AK-lesions within the former treatment area</measure>
    <time_frame>at 6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of newly occurred dermal adverse and serious adverse events on the previous treatment area</measure>
    <time_frame>at 6 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">16</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Patients ex. Arm 1 SP848-AK-1101 trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Patients ex. Arm 2 SP848-AK-1101 trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>Patients ex. Arm 3 SP848-AK-1101 trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <description>Patients ex. Arm 4 SP848-AK-1101 trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <description>Patients ex. Arm 5 SP848-AK-1101 trial</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with complete clinical clearance (i.e. no previously existing AK-lesion present)
        at the end of the trial SP848-AK-1101 or Non- Responder who withdrew from the trial
        prematurely.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent.

          -  Participation in the previous clinical trial SP848-AK-1101.

          -  Patient with complete clinical clearance (i.e. no previously existing AK-lesion
             present) at the end of the trial SP848-AK-1101 or Non-Responder who withdrew from the
             trial prematurely.

        Exclusion Criteria:

          -  Evidence of unstable or uncontrolled clinically significant medical conditions as
             determined by the investigator (e.g., cardiovascular, immunological, hematologic,
             hepatic, neurologic, renal, endocrine, collagen-vascular, infectious,
             gastrointestinal abnormalities or diseases).

          -  Evidence of systemic cancer.

          -  Dermatological disease or condition in the former treatment or surrounding area that
             might impair trial assessments (e.g., rosacea, atopic dermatitis, eczema) as assessed
             by the investigator.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars E French, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinic of Dermatology, Zurich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hauttumorcentrum Charité (HTCC)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Zentrum Bonn - Friedensplatz</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautzentrum</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KLINIKUM VEST GmbH Knappschaftskrankenhaus</name>
      <address>
        <city>Recklinghausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St.Gallen</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Zurich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 24, 2013</lastchanged_date>
  <firstreceived_date>March 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
